Cargando…
Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice
Activation of osteoclast formation and function is crucial for the development of osteolytic diseases such as osteoporosis. RANKL (receptor activator of nuclear factor-κB ligand) activates NF-κB (nuclear factor κB), MAPK (mitogen-activated protein kinase), and NFATc1 (nuclear factor of activated T-c...
Autores principales: | Huang, Bao, Wang, Jiasheng, Zhang, Xuyang, Xie, Ziang, Wu, Hao, Liu, Junhui, Jie, Zhiwei, Zhao, Xiangde, Qin, An, Fan, Shunwu, Chen, Jian, Zhao, Fengdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704231/ https://www.ncbi.nlm.nih.gov/pubmed/31474861 http://dx.doi.org/10.3389/fphar.2019.00900 |
Ejemplares similares
-
Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021) -
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
por: Huang, Jun-ming, et al.
Publicado: (2018) -
Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020) -
Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
por: Wang, Jia, et al.
Publicado: (2020) -
Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
por: Ma, Min, et al.
Publicado: (2022)